OncoSec Medical Inc (NASDAQ:ONCS) CEO Daniel J. O’connor purchased 16,667 shares of OncoSec Medical stock in a transaction on Monday, February 5th. The shares were acquired at an average cost of $1.50 per share, for a total transaction of $25,000.50. Following the purchase, the chief executive officer now owns 16,667 shares in the company, valued at $25,000.50. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

OncoSec Medical Inc (ONCS) opened at $1.74 on Thursday. The firm has a market capitalization of $76.44, a price-to-earnings ratio of -1.64 and a beta of 3.34. OncoSec Medical Inc has a 52-week low of $0.88 and a 52-week high of $2.95.

ONCS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of OncoSec Medical in a research note on Thursday, November 9th. Maxim Group set a $5.00 price target on OncoSec Medical and gave the stock a “buy” rating in a research note on Thursday, December 14th. Finally, ValuEngine lowered OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $5.33.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/02/08/daniel-j-oconnor-acquires-16667-shares-of-oncosec-medical-inc-oncs-stock.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.